David Meeker joined Genzyme in 1994.

Dr. Meeker was medical director and then vice president, medical affairs, responsible for the development of therapeutic products including products in the current LSD portfolio prior to his promotion to senior vice president in 1998.  In 2000 he assumed the position as business unit leader for Genzyme’s lysosomal storage disease and Thyrogen® programs in Europe.  In March 2003 he was promoted to president of the Global LSD Business unit.
 
Prior to joining Genzyme, Dr. Meeker was the director of the Pulmonary Critical Care Fellowship at the Cleveland Clinic Foundation. 
 
He attended Dartmouth College and received his M.D. from the University of Vermont Medical School. Dr. Meeker completed an Internal Medicine residency at Beth Israel Hospital in Boston and a pulmonary/critical care fellowship at Boston University.  He completed the Advanced Management Program at Harvard Business School in 2000.